GSK Inflammation Drug Lands New FDA Nod in COPD, Stiffening Competition With Sanofi Med
GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that’s driven by eosinophils, a type of immune cell. The antibody drug will compete against the blockbuster Sanofi product Dupixent, which expanded its FDA approval to COPD last year. The post GSK Inflammation Drug Lands New FDA Nod in COPD, Stiffening Competition With Sanofi Med appeared first on MedCity News.
GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that’s driven by eosinophils, a type of immune cell. The antibody drug will compete against the blockbuster Sanofi product Dupixent, which expanded its FDA approval to COPD last year.
The post GSK Inflammation Drug Lands New FDA Nod in COPD, Stiffening Competition With Sanofi Med appeared first on MedCity News.
